Telomere maintenance is essential for the unlimited division of cancer cells. Most tumors reactivate telomerase, but 10-15% use the alternative lengthening of telomeres (ALT) mechanism, which is based on homologous recombination. ALT telomeres stand out for their highly heterogeneous length, the accumulation of G-quadruplexes and R-loops, and the production of extrachromosomal telomeric repeats such as C-circles. This work sits off to the side of the main body of research, yet it echoes neighboring studies on genes that predict breast cancer outcomes, immune cell exhaustion, and tumor genealogy: all of them deal with how a cell copes with stress and DNA damage. Here, however, the focus shifts to one specific enzyme and its role in the ALT mechanism itself.
The researchers used ALT+ cell lines (U2OS, Saos2) and TEL+ cell lines (A549, H460, HeLa). Recruitment of hPIF1 to damaged telomeres was tracked with the TRF1-FokI system, which makes it possible to induce double-strand breaks specifically in telomeres. hPIF1 activity was suppressed either with a small-molecule inhibitor, PIF1i, or with siRNA. DNA damage was assessed by γH2AX and TRF2 foci, single-stranded DNA by the 4SET method, and C-circles by the C-circle assay. Telomere length and chromosome fusions were measured at the level of individual DNA molecules using optical mapping (SMTA-OM). G-quadruplexes were visualized by super-resolution microscopy with antibodies against G4.
Inhibiting hPIF1 in ALT+ cells produced a twofold increase in γH2AX/TRF2 foci, pointing to telomere damage. At the same time, the formation of C-rich single-stranded DNA and C-circles dropped, meaning that hPIF1 promotes the production of extrachromosomal telomeric repeats. Average telomere length decreased by 12%, and the frequency of chromosome fusions rose by 71%. In cells deficient in FANCM, where replication stress is sharply elevated, co-depletion of hPIF1 weakened the stress response, reduced BLM recruitment, and cut C-circle formation by more than 50%. Inhibiting hPIF1 or FANCM also caused G-quadruplexes to accumulate across the genome, telomeres included. Finally, suppressing hPIF1 lowered the viability of both ALT+ and TEL+ cancer cells, with the inhibitor's EC50 ranging from 60 to 200 µM.
Unlike neighboring studies that describe correlations between gene expression and outcomes, this work shows for the first time a direct functional link between hPIF1 and the ALT mechanism. It demonstrates that hPIF1 is not merely a marker but an active participant in two key processes: unwinding G-quadruplexes and triggering BIR. That explains why ALT cells depend on hPIF1 for survival and makes it an attractive therapeutic target, especially for the 10-15% of tumors in which telomerase is inactive.
The field could move toward working out the molecular details of how hPIF1 switches between unwinding G4 and stimulating BIR. There may be post-translational modifications or partner proteins that steer hPIF1 down one path or the other. Studying combinations of hPIF1 inhibitors with other agents also looks promising, particularly for ALT+ tumors, which are often resistant to standard therapy.
The results will affect oncology by offering a new drug target, and fundamental telomere biology by deepening our understanding of how cells balance replication stress against recombination-based synthesis.
Test the efficacy of PIF1i in animal models of ALT+ tumors and assess its toxicity to normal tissues. It would also be worth investigating how hPIF1 inhibition affects other DNA repair pathways in cancer cells.
The work speaks directly to an unsolved problem in cancer biology: why some tumors choose ALT while others choose telomerase, and how that choice determines sensitivity to therapy. It also touches on a fundamental question about how cells cope with replication stress in hard-to-replicate regions of the genome, such as telomeres.
The PIF1i inhibitor (Compound 1) was checked in the lab by HPLC, mass spectrometry, and NMR, and its purity came out close to 99%. It is a rare case of a small molecule against a helicase being so thoroughly characterized before use in cell experiments.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.